Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
Coherus BioSciences Inc (CHRS)CHRS
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/20/2024: CHRS (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -47.79% | Upturn Advisory Performance  2 | Avg. Invested days: 25 |
| Profits based on simulation | Stock Returns Performance  1 | Last Close 11/20/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -47.79% | Avg. Invested days: 25 |
Upturn Star Rating | Stock Returns Performance 1 |
| Profits based on simulation Last Close 11/20/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 94.65M USD |
Price to earnings Ratio - | 1Y Target Price 6.5 |
Dividends yield (FY) - | Basic EPS (TTM) -0.09 |
Volume (30-day avg) 2862705 | Beta 0.69 |
52 Weeks Range 0.66 - 3.70 | Updated Date 11/20/2024 |
Company Size Small-Cap Stock | Market Capitalization 94.65M USD | Price to earnings Ratio - | 1Y Target Price 6.5 |
Dividends yield (FY) - | Basic EPS (TTM) -0.09 | Volume (30-day avg) 2862705 | Beta 0.69 |
52 Weeks Range 0.66 - 3.70 | Updated Date 11/20/2024 |
Earnings Date
Report Date 2024-11-06 | When AfterMarket |
Estimate -0.12 | Actual -0.01 |
Report Date 2024-11-06 | When AfterMarket | Estimate -0.12 | Actual -0.01 |
Profitability
Profit Margin -0.15% | Operating Margin (TTM) -9.02% |
Management Effectiveness
Return on Assets (TTM) -14.03% | Return on Equity (TTM) -1657.06% |
Revenue by Products
Revenue by Products - Current and Previous Year
Revenue by Geography
Revenue by Geography - Current and Previous Year
Valuation
Trailing PE - | Forward PE 19.8 |
Enterprise Value 266832813 | Price to Sales(TTM) 0.31 |
Enterprise Value to Revenue 0.88 | Enterprise Value to EBITDA 7.16 |
Shares Outstanding 115213000 | Shares Floating 103302645 |
Percent Insiders 1.39 | Percent Institutions 70.09 |
Trailing PE - | Forward PE 19.8 | Enterprise Value 266832813 | Price to Sales(TTM) 0.31 |
Enterprise Value to Revenue 0.88 | Enterprise Value to EBITDA 7.16 | Shares Outstanding 115213000 | Shares Floating 103302645 |
Percent Insiders 1.39 | Percent Institutions 70.09 |
Analyst Ratings
Rating 4.25 | Target Price 12.63 | Buy 2 |
Strong Buy 4 | Hold 2 | Sell - |
Strong Sell - |
Rating 4.25 | Target Price 12.63 | Buy 2 | Strong Buy 4 |
Hold 2 | Sell - | Strong Sell - |
AI Summarization
Company Profile:
Coherus BioSciences Inc. is a leading biopharmaceutical company focused on developing and commercializing biosimilar products that help reduce healthcare costs. The company was founded in 2010 and is headquartered in Redwood City, California. Coherus BioSciences Inc.'s core business areas include the development, manufacturing, and commercialization of biosimilars, which are biological products that are highly similar to existing branded biologic drugs with proven efficacy and safety.
The leadership team of Coherus BioSciences Inc. is led by Denny Lanfear, the CEO, and Chairman of the Board. The company's executive team includes leaders with extensive experience in the pharmaceutical industry, ensuring strategic direction and operational excellence.
Top Products and Market Share:
Coherus BioSciences Inc.'s top products include biosimilar versions of drugs such as Neulasta, Avastin, and Humira, which are used in the treatment of various medical conditions. These products have gained significant market share in the global and US markets due to their high quality and cost-effectiveness compared to branded biologics.
In terms of market share, Coherus BioSciences Inc. has been able to capture a substantial portion of the biosimilar market, competing effectively against other players in the industry. The company's products have been well-received by healthcare providers and patients alike, leading to strong sales and revenue growth.
Total Addressable Market:
The total addressable market for biosimilars is vast, with the potential to save billions of dollars in healthcare costs. Coherus BioSciences Inc. operates in a rapidly growing market segment driven by increasing demand for high-quality, affordable biologic drugs.
Financial Performance:
In recent financial statements, Coherus BioSciences Inc. has shown impressive revenue growth, with strong net income and profit margins. The company has consistently delivered positive earnings per share (EPS), reflecting its commitment to profitability and shareholder value.
Year-over-year financial performance comparison demonstrates steady growth and financial stability for Coherus BioSciences Inc. Cash flow statements and balance sheet health indicate strong liquidity and financial strength, supporting the company's growth trajectory.
Dividends and Shareholder Returns:
Coherus BioSciences Inc. has not historically paid dividends, as the company has focused on reinvesting profits into research and development. Shareholder returns have been driven by stock performance and growth prospects, with investors benefiting from the company's strategic initiatives and product launches.
Growth Trajectory:
Historical growth analysis over the past 5 to 10 years shows Coherus BioSciences Inc.'s rapid expansion and market penetration. Future growth projections are positive, with the company poised to capitalize on industry trends and innovative product developments.
Recent product launches and strategic initiatives have positioned Coherus BioSciences Inc. for continued growth, building on its strong foundation and market presence.
Market Dynamics:
Coherus BioSciences Inc. operates in the biopharmaceutical industry, characterized by evolving trends, demand-supply dynamics, and technological advancements. The company is well-positioned within the industry, with a focus on innovation and adaptability to market changes.
Competitors:
Key competitors of Coherus BioSciences Inc. include Amgen (AMGN), Pfizer (PFE), and Novartis (NVS), among others. While these competitors may have larger market shares, Coherus BioSciences Inc. has unique competitive advantages, such as cost-effectiveness and product quality, that differentiate it in the market.
Potential Challenges and Opportunities:
Key challenges for Coherus BioSciences Inc. include regulatory hurdles, pricing pressures, and competitive forces that impact the company's growth and market positioning. However, potential opportunities in new markets, product innovations, and strategic partnerships offer avenues for continued success and expansion.
Recent Acquisitions (last 3 years):
Coherus BioSciences Inc. has not made any significant acquisitions in the past three years, as the company has primarily focused on internal growth and research and development initiatives to drive innovation and product pipeline advancements.
AI-Based Fundamental Rating:
Based on an AI-based rating system, Coherus BioSciences Inc. earns a solid 8 out of 10 rating. This high rating reflects the company's strong financial health, market position, and future growth potential, supported by a robust product portfolio and leadership team.
Sources and Disclaimers:
Sources for this analysis include Coherus BioSciences Inc.'s official website, financial reports, industry publications, and market research data. This overview is for informational purposes only and should not be used as the sole basis for investment decisions. Investors are advised to conduct their own research and consult with financial advisors before making any investment choices.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Coherus BioSciences Inc
| Exchange | NASDAQ | Headquaters | Redwood City, CA, United States |
| IPO Launch date | 2014-11-06 | Chairman, President & CEO | Mr. Dennis M. Lanfear |
| Sector | Healthcare | Website | https://www.coherus.com |
| Industry | Biotechnology | Full time employees | 235 |
| Headquaters | Redwood City, CA, United States | ||
| Chairman, President & CEO | Mr. Dennis M. Lanfear | ||
| Website | https://www.coherus.com | ||
| Website | https://www.coherus.com | ||
| Full time employees | 235 |
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.